

IN THE CLAIMS:

AMC57 --1. (Once Amended) A [An] mucosal adjuvant composition comprising a glucose monomers linked together in branched [chains by] beta-1,3 linked chains with beta-1,3,6 linked branching points comprising beta-1,3 linked or beta 1,6 linked side chains [linkages and beta-1,6 linkages which modulate the effect of medicinal substances administered onto mucosal surfaces].—

Please cancel claims 9-12 without prejudice.

REMARKS

Applicant has amended claim 1 to more specifically define the structural characteristics of the glucan component of the claimed mucosal adjuvant composition. Furthermore, the claim has been amended to more clearly recite that the claimed adjuvant is a mucosal adjuvant is a mucosal adjuvant.

Arguably ambiguous claim language has been deleted.

Claims 9-12 have been deleted from consideration herein while the Applicant has retained the right to file divisional application(s) to the subject matter of said claims at anytime during the pendency of the subject application.

The Benach et al reference from Infection and Immunology, Vol. 35 No. 3 1982; pp 947-957 has been cited against claims 1, 2, 4-9, 12 and 13 as the Examiner asserts that said reference discloses a yeast cell wall glucan for use as an adjuvant.